Build bone first for your patients at very high fracture risk
• Recommended as the 1
st line therapy for patients with very high risk of fractures
1
• Significant BMD improvements vs teriparatide in 1 year of therapy
2
• Reduced hip, vertebral, and non-vertebral fractures vs alendronate
*3
• Convenient monthly subcutaneous administration
4
*In the ARCH study, patients receiving 1 year of romosozumab followed by 2 years of alendronate significantly reduced hip, vertebral, and non-vertebral fractures vs patients receiving 3 years of alendronate alone.
References:
1. Camacho PM, Petak SM, et al. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis- 2020 Update. Endocr Pract. 2020; 26(5): 564-570.
2. Langdahl BL, Libanati C, et al. Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet. 2017; 390(10102): 1585-1594.
3. Saag KG, Petersen J, Brandi ML, et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med. 2017; 377(15): 1417-1427.
4. Evenity HK prescribing information. March 2020.
HK-08489-EVE-2022-Jun
AMGEN HONG KONG LIMITED
Suites 407-412, 4/F, One Island East,
18 Westlands Road, Quarry Bay, Hong Kong
Tel: (+852) 2843 1178 • Fax: (+852) 2808 2820